Last reviewed · How we verify
NCT06015971
Omega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer
NA trial testing omega-3 in Sarcopenia in 40 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Maimónides Biomedical Research Institute of Córdoba |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 40 |
| Start date | 1 July 2023 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- omega-3
- Standard
Conditions studied
- Sarcopenia — all drugs for Sarcopenia →
Sponsor
Maimónides Biomedical Research Institute of Córdoba
Who can join
18 and older, any sex, with Sarcopenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sarcopenia is a frequent complication in patients with cancer and chronic diseases, it is characterized by decreased muscle strength and fatigue due to reduced skeletal muscle mass, which is accompanied by atrophy and decreased quality of muscle tissue. In all cases, it negatively impacts treatment tolerance, clinical outcomes and survival, in consequence, quality of life of these patients decreases while morbidity, mortality and costs increase. In this context, appropriate nutritional screening and early nutrition support are extremely recommended, to this aim, in some cases, oral nutritional supplements (ONS) are necessary; ONS could have a standard formula or be enriched with specific nutrients (arginine, glutamine, branched chain amino acids, n-3 fatty acids, and nucleotides), which can modulate the activity of the immune system and provide an additional benefit beyond the nutritional support, this intervention type is called immunonutrition. Despite these possible benefits, their utility has been proven in few clinical scenarios, for example in with patients with upper gastrointestinal cancer undergoing surgical resection; based on this, current guidelines recommend that patients should receive oral/enteral nutritional support with an specific formula enriched in immunonutrients (with arginine, n-3 fatty acids or nucleotides) , but there is a lack of evidence for supporting its use in other clinical conditions including patients with cancer that receive systemic treatment
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06015971
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of omega-3
Trials testing the same drug.
- NCT05941754 — A Clinical Study of Omega-3 on Depression and Cognition · NA · unknown
Other recruiting trials for Sarcopenia
Currently open trials in the same condition.
- NCT07500376 — Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery · recruiting
- NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke · NA · recruiting
- NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia · NA · recruiting
- NCT07494916 — Effects of Functional Task Training on Muscle Health and Function in Older Adults With Sarcopenia · NA · active not recruiting
- NCT07426159 — AI-Guided Sarcopenia Risk Assessment and Detection · NA · active not recruiting
Other Maimónides Biomedical Research Institute of Córdoba trials
Trials by the same sponsor.
- NCT06783491 — Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Ad · Phase 3 · not yet recruiting
- NCT07479303 — Vitamin D Status in Young Medical Residents · completed
- NCT07178379 — Hysteroscopy Anesthesia for Relief of Pain · NA · not yet recruiting
- NCT06712485 — Biomarkers in EV Associated With Marrow Adiposity in Anorexia · not yet recruiting
- NCT06579846 — 12-Month Efficacy of Exercise and Cytisinicline for Tobacco Abstinence · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06015971 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Maimónides Biomedical Research Institute of Córdoba
- Last refreshed: 6 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06015971.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing